Base de dados : MEDLINE
Pesquisa : D03.383.725.762.740 [Categoria DeCS]
Referências encontradas : 1490 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 149 ir para página                         

  1 / 1490 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29230265
[Au] Autor:Maneh N; Apetse K; Diatewa BM; Domingo SA; Agba AI; Ayena KD; Balogou KA; Balo KP
[Ad] Endereço:Université de Lomé, Faculté des Sciences de la Santé, Lomé, Togo.
[Ti] Título:[Juvenile myasthenia gravis in sub-Saharan Africa: a case study of two consanguine sisters born from consanguinity in Togo].
[Ti] Título:Myasthénie juvénile oculaire en Afrique Subsaharienne: cas de deux sÅ“urs germaines issues d'un mariage consanguin au Togo..
[So] Source:Pan Afr Med J;28:63, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:Myasthenia gravis is a rare acquired autoimmune pathology causing neuromuscular transmission impairment. Juvenile onset of myasthenia gravis is often characterized by ocular involvement. We report two cases of ocular juvenile myasthenia gravis (JMG) in two siblings. They were two young girls, XA and XB, aged 11 and 9 years, of Malian origin, residing in Togo, born from first-degree of consanguinity presenting to Ophthalmology due to progressive decrease in visual acuity. XA showed visual acuity 8/10 on both eyes while XB showed improvement in visual acuity from 3/10 to 7/10 using a pinhole occluder, suggesting ametropia. XA had a 2-year history of bilateral ptosis lifting the upper eyelid of 7 mm, while XB had a 3-year history of bilateral ptosis with no lifting of the upper eyelid. Ice pack test was strongly positive in both patients. They had Cogan's lid twitch with paresis of the oculomotor nerve without diplopia. The dosage of acetylcholine receptor autoantibodies was normal. The diagnosis of JMG associated with ametropia was suspected. Ametropia was corrected by glasses and a specific treatment with pyridostigmine was initiated, but both patients were lost to follow-up. Autoimmune myasthenia gravis with inaugural ophthalmologic manifestation is rare but it can occur among children living in sub-Saharan Africa. Studies should be conducted to establish the features of this disease.
[Mh] Termos MeSH primário: Miastenia Gravis/diagnóstico
Doenças do Nervo Oculomotor/etiologia
Erros de Refração/etiologia
Acuidade Visual
[Mh] Termos MeSH secundário: Idade de Início
Criança
Consanguinidade
Progressão da Doença
Feminino
Seres Humanos
Perda de Seguimento
Miastenia Gravis/complicações
Miastenia Gravis/imunologia
Brometo de Piridostigmina/administração & dosagem
Togo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.28.63.13709


  2 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28985942
[Au] Autor:Azzolin VF; Barbisan F; Lenz LS; Teixeira CF; Fortuna M; Duarte T; Duarte MMFM; da Cruz IBM
[Ad] Endereço:Programa de Pós-Graduação em Farmacologia, Universidade Federal de Santa Maria, Av Roraima 1000, Prédio 20. Zip Code 97105-900 Santa Maria, RS, Brazil.
[Ti] Título:Effects of Pyridostigmine bromide on SH-SY5Y cells: An in vitro neuroblastoma neurotoxicity model.
[So] Source:Mutat Res;823:1-10, 2017 Nov.
[Is] ISSN:1873-135X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Pyridostigmine bromide (PB) is a reversible acetylcholinesterase (AChE) inhibitor and the first-choice for the treatment of symptoms associated with myasthenia gravis and other neuromuscular junction disorders. However, evidence suggested that PB could be associated with the Gulf War Illness characterised by the presence of fatigue, headaches, cognitive dysfunction, and musculoskeletal respiratory and gastrointestinal disturbances. Given that a potential neurotoxic effect of PB has not yet been completely elucidated, the present investigation used neural SH-SY5Y cells to evaluate the effect of PB on the cellular viability, cell apoptosis, modulation of the cell cycle, oxidative stress, and genotoxicity variables, which indicate neurodegeneration. As expected, a PB concentration curve based on the therapeutic dose of the drug showed an inhibition of the AChE activity. However, this effect was transient and did not involve differential AChE gene regulation by PB. These results confirmed that undifferentiated SH-SY5Y cells can be used as a cholinergic in vitro model. In general, PB did not trigger oxidative stress, and at a slightly higher PB concentration (80ng/mL), higher levels of protein carbonylation and DNA damage were detected, as determined by the marker 8-deoxyguanosine. The PB genotoxic effects at 80ng/mL were confirmed by the upregulation of the p53 and DNA methyltransferase 1 (DNMT1) genes, which are associated with cellular DNA repair. PB at 40ng/mL, which is the minimal therapeutic dose, led to higher cell proliferation and mitochondrial activity compared with the control group. The effects of PB were corroborated by the upregulation of the telomerase gene. In summary, despite the methodological constrains related to the in vitro protocols, our results suggested that exposure of neural cells to PB, without other chemical and physical stressors did not cause extensive toxicity or indicate any neurodegeneration patterns.
[Mh] Termos MeSH primário: Inibidores da Colinesterase/toxicidade
Neurônios/efeitos dos fármacos
Brometo de Piridostigmina/toxicidade
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
DNA (Citosina-5-)-Metiltransferase 1
DNA (Citosina-5-)-Metiltransferases/genética
DNA (Citosina-5-)-Metiltransferases/metabolismo
Dano ao DNA/efeitos dos fármacos
Reparo do DNA/efeitos dos fármacos
Seres Humanos
Mitocôndrias/efeitos dos fármacos
Mitocôndrias/metabolismo
Miastenia Gravis/tratamento farmacológico
Neurônios/citologia
Estresse Oxidativo/efeitos dos fármacos
Proteína Supressora de Tumor p53/genética
Proteína Supressora de Tumor p53/metabolismo
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Tumor Suppressor Protein p53); EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1); EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases); EC 2.1.1.37 (DNMT1 protein, human); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171008
[St] Status:MEDLINE


  3 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28794253
[Au] Autor:Byun JI; Moon J; Kim DY; Shin H; Sunwoo JS; Lim JA; Kim TJ; Lee WJ; Lee HS; Jun JS; Park KI; Lee ST; Jung KH; Jung KY; Lee SK; Chu K
[Ad] Endereço:From the Department of Neurology (J.-I.B., J.M., D.-Y.K., H.S., J.-S.S., J.-A.L., T.-J.K., W.-J.L., H.S.L., J.-S.J. S.-T.L., K.-H.J., K.-Y.J., S.K.L., K.C.), Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Center for Medical Innovations, Biomedical Research Institute, Seoul National
[Ti] Título:Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
[So] Source:Neurology;89(10):1078-1086, 2017 Sep 05.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH). METHODS: This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine + pyridostigmine. The patients were followed up at 1 and 3 months after treatment. The primary outcome measures were improvement in orthostatic blood pressure (BP) drop at 3 months. Secondary endpoints were improvement of the orthostatic BP drop at 1 month and amelioration of the questionnaire score evaluating OH-associated symptoms. RESULTS: Orthostatic systolic and diastolic BP drops improved significantly at 3 months after treatment in all treatment groups. Orthostatic symptoms were significantly ameliorated during the 3-month treatment, and the symptom severity was as follows: midodrine only < midodrine + pyridostigmine < pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients. CONCLUSIONS: Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms. CLINICALTRIALSGOV IDENTIFIER: NCT02308124. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment with midodrine alone, pyridostigmine alone, or both midodrine and pyridostigmine is safe and has similar effects in improving orthostatic BP drop up to 3 months.
[Mh] Termos MeSH primário: Hipotensão Ortostática/tratamento farmacológico
Midodrina/administração & dosagem
Brometo de Piridostigmina/administração & dosagem
Vasoconstritores/administração & dosagem
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos alfa 1/administração & dosagem
Agonistas de Receptores Adrenérgicos alfa 1/efeitos adversos
Pressão Sanguínea/efeitos dos fármacos
Inibidores da Colinesterase/administração & dosagem
Inibidores da Colinesterase/efeitos adversos
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Midodrina/efeitos adversos
Brometo de Piridostigmina/efeitos adversos
Autorrelato
Fatores de Tempo
Resultado do Tratamento
Vasoconstritores/efeitos adversos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Agonists); 0 (Cholinesterase Inhibitors); 0 (Vasoconstrictor Agents); 6YE7PBM15H (Midodrine); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000004340


  4 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28500787
[Au] Autor:Locker AR; Michalovicz LT; Kelly KA; Miller JV; Miller DB; O'Callaghan JP
[Ad] Endereço:Health Effects Laboratory Division, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA.
[Ti] Título:Corticosterone primes the neuroinflammatory response to Gulf War Illness-relevant organophosphates independently of acetylcholinesterase inhibition.
[So] Source:J Neurochem;142(3):444-455, 2017 Aug.
[Is] ISSN:1471-4159
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Gulf War Illness (GWI) is a chronic multi-symptom disorder affecting veterans of the 1991 Gulf War. Among the symptoms of GWI are those associated with sickness behavior, observations suggestive of underlying neuroinflammation. We have shown that exposure of mice to the stress hormone, corticosterone (CORT), and to diisopropyl fluorophosphate (DFP), as a nerve agent mimic, results in marked neuroinflammation, findings consistent with a stress/neuroimmune basis of GWI. Here, we examined the contribution of irreversible and reversible acetylcholinesterase (AChE) inhibitors to neuroinflammation in our mouse model of GWI. Male C57BL/6J mice received 4 days of CORT (400 mg/L) in the drinking water followed by a single dose of chlorpyrifos oxon (CPO; 8 mg/kg, i.p.), DFP (4 mg/kg, i.p.), pyridostigmine bromide (PB; 3 mg/kg, i.p.), or physostigmine (PHY; 0.5 mg/kg, i.p.). CPO and DFP alone caused cortical and hippocampal neuroinflammation assessed by qPCR of tumor necrosis factor-alpha, IL-6, C-C chemokine ligand 2, IL-1ß, leukemia inhibitory factor and oncostatin M; CORT pretreatment markedly augmented these effects. Additionally, CORT exposure prior to DFP or CPO enhanced activation of the neuroinflammation signal transducer, signal transducer and activator of transcription 3 (STAT3). In contrast, PHY or PB alone or with CORT pretreatment did not produce neuroinflammation or STAT3 activation. While all of the CNS-acting AChE inhibitors (DFP, CPO, and PHY) decreased brain AChE activity, CORT pretreatment abrogated these effects for the irreversible inhibitors. Taken together, these findings suggest that irreversible AChE inhibitor-induced neuroinflammation and particularly its exacerbation by CORT, result from non-cholinergic effects of these compounds, pointing potentially to organophosphorylation of other neuroimmune targets.
[Mh] Termos MeSH primário: Acetilcolinesterase/metabolismo
Encéfalo/efeitos dos fármacos
Inibidores da Colinesterase/toxicidade
Corticosterona/farmacologia
Guerra do Golfo
Organofosfatos/metabolismo
[Mh] Termos MeSH secundário: Animais
Encéfalo/metabolismo
Modelos Animais de Doenças
Masculino
Camundongos Endogâmicos C57BL
Síndrome do Golfo Pérsico/patologia
Brometo de Piridostigmina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Organophosphates); EC 3.1.1.7 (Acetylcholinesterase); KVI301NA53 (Pyridostigmine Bromide); W980KJ009P (Corticosterone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170514
[St] Status:MEDLINE
[do] DOI:10.1111/jnc.14071


  5 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28418831
[Au] Autor:Kassa J; Korábecný J; Nepovimová E
[Ad] Endereço:Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic. kassa@pmfhk.cz.
[Ti] Título:The Evaluation of Benefit of Newly Prepared Reversible Inhibitors of Acetylcholinesterase and Commonly Used Pyridostigmine as Pharmacological Pretreatment of Soman-Poisoned Mice.
[So] Source:Acta Medica (Hradec Kralove);60(1):37-43, 2017.
[Is] ISSN:1211-4286
[Cp] País de publicação:Czech Republic
[La] Idioma:eng
[Ab] Resumo:AIM: The ability of four newly prepared reversible inhibitors of acetylcholinesterase (6-chlorotacrine, 7-phenoxytacrine, compounds 1 and 2) and currently used carbamate pyridostigmine to increase the resistance of mice against soman and the efficacy of antidotal treatment of soman-poisoned mice was evaluated. METHODS: The evaluation of the effect of pharmacological pretreatment is based on the identification of changes of soman-induced toxicity that was evaluated by the assessment of its LD50 value and its 95% confidence limit using probitlogarithmical analysis of death occurring within 24 h after administration of soman. RESULTS: 6-chlorotacrine was only able to markedly protect mice against acute toxicity of soman. In addition, the pharmacological pretreatment with 6-chlorotacrine or compound 2 was able to increase the efficacy of antidotal treatment (the oxime HI-6 in combination with atropine) of soman-poisoned mice. The other newly prepared reversible inhibitors of acetylcholinesterase (7-phenoxytacrine, compound 1) as well as commonly used pyridostigmine did not influence the efficacy of antidotal treatment. CONCLUSION: These findings demonstrate that pharmacological pretreatment of somanpoisoned mice can be promising and useful in the case of administration of 6-chlorotacrine and partly compound 2.
[Mh] Termos MeSH primário: Inibidores da Colinesterase/farmacologia
Compostos de Piridínio/farmacologia
Soman/envenenamento
[Mh] Termos MeSH secundário: Animais
Quimioterapia Combinada
Seres Humanos
Isoquinolinas
Masculino
Camundongos
Compostos de Piridínio/administração & dosagem
Brometo de Piridostigmina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1,10-bis(pyridinium)decane); 0 (1,8-bis(4-tert-butylpyridinium)oct-1,8-diyl); 0 (1,8-bis(isoquinolinium)-oct-1,8-diyl); 0 (Cholinesterase Inhibitors); 0 (Isoquinolines); 0 (Pyridinium Compounds); 96-64-0 (Soman); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.14712/18059694.2017.45


  6 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28080955
[Au] Autor:Singh G; Hodgson T; Clarke DE
[Ad] Endereço:Medical Student in Internal Medicine at the University of Otago School of Medicine in Dunedin, New Zealand. singu331@student.otago.ac.nz.
[Ti] Título:Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case.
[So] Source:Perm J;21, 2017.
[Is] ISSN:1552-5775
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Pyridostigmine is an acetylcholinesterase inhibitor commonly used in the treatment of myasthenia gravis. We describe a patient who developed a rash after recently being started on pyridostigmine and give a general review of leukocytoclastic vasculitis. CASE PRESENTATION: A 91-year-old man was diagnosed with ocular myasthenia gravis. He was started on pyridostigmine, and 2 weeks later he developed a rash. The rash was biopsied and found to be secondary to leukocytoclastic vasculitis; the pyridostigmine was stopped, loratadine was started, and the rash resolved. DISCUSSION: Leukocytoclastic vasculitis is commonly caused by a hypersensitivity reaction to medications, or it can be associated with certain medical conditions. We present a brief review of the most common medications and medical conditions known to cause this reaction, but to our knowledge this is the first description of pyridostigmine causing this reaction.
[Mh] Termos MeSH primário: Loratadina/uso terapêutico
Miastenia Gravis/tratamento farmacológico
Brometo de Piridostigmina/efeitos adversos
Vasculite Leucocitoclástica Cutânea/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Inibidores da Colinesterase/efeitos adversos
Inibidores da Colinesterase/uso terapêutico
Seres Humanos
Masculino
Brometo de Piridostigmina/uso terapêutico
Vasculite Leucocitoclástica Cutânea/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 7AJO3BO7QN (Loratadine); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170113
[St] Status:MEDLINE


  7 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28062435
[Au] Autor:Joseph CJ; Khoo TB; Lee KY
[Ad] Endereço:Paediatric Institute, Kuala Lumpur General Hospital, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
[Ti] Título:Flaccid paralysis in an infant associated with a dirty wound and application of honey.
[So] Source:BMJ Case Rep;2017, 2017 Jan 06.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:An infant, who was born preterm at 36 weeks, presented with fever and ulcer at umbilical region which progressed to necrotising fasciitis of anterior abdominal wall. He was treated with intravenous penicillin, intravenous cloxacillin and local application of medicated honey. Subsequently, he required wound debridement. Postoperatively, he required prolonged invasive ventilation due to poor respiratory effort which was associated with hypotonia and areflexia. Nerve conduction study revealed absent responses. The diagnosis of infant botulism was made based on the clinical presentation, nerve conduction study and his clinical progress. Botulinum immunoglobulin was not available. He was treated with intravenous immunoglobulin and oral pyridostigmine. He was successfully extubated after 37 days, and currently the patient is doing well.
[Mh] Termos MeSH primário: Botulismo/tratamento farmacológico
Inibidores da Colinesterase/uso terapêutico
Fasciite Necrosante/terapia
Mel
Imunoglobulinas Intravenosas/uso terapêutico
Brometo de Piridostigmina/uso terapêutico
[Mh] Termos MeSH secundário: Botulismo/diagnóstico
Desbridamento/métodos
Fasciite Necrosante/microbiologia
Seres Humanos
Lactente
Masculino
Paralisia/microbiologia
Resultado do Tratamento
Úlcera/microbiologia
Úlcera/terapia
Umbigo
Infecção dos Ferimentos/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Immunoglobulins, Intravenous); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE


  8 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28061919
[Au] Autor:Jagathesan T; O'Brien MD
[Ti] Título:Myasthenia Gravis and Its Aeromedical Implications.
[So] Source:Aerosp Med Hum Perform;88(1):30-33, 2017 Jan 01.
[Is] ISSN:2375-6314
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Myasthenia gravis is an autoimmune condition where antibodies form against the acetylcholine receptors at the neuromuscular junction, eventually causing damage to the motor end plate. The clinical features include muscle fatigability as well as ocular, bulbar, and limb weakness, which can have implications on the role of a pilot or air traffic controller. This retrospective study reviewed the United Kingdom Civil Aviation Authority (UK CAA) experience of myasthenia gravis. METHODS: A search of the United Kingdom Civil Aviation Authority medical records database from 1990 to 2016 identified 11 individuals with a diagnosis of myasthenia gravis. Data were extracted for the class of medical certificate, age at diagnosis, symptoms, acetylcholine receptor antibody status, treatment, the time from diagnosis to loss of medical certification, and the reasons for loss of certification. RESULTS: There were two Class 1 certificate holders (for professional flying) and six Class 2 certificate holders (for private pilot flying) and three air traffic controllers. The mean and median ages at diagnosis were 53 and 57 yr, respectively, with a range of 28-67 yr. The mean and median intervals from diagnosis to loss of certification were 22 and 11 mo, respectively, with a range of 0 to 108 mo. CONCLUSION: The aeromedical implications of myasthenia gravis, including complications, types of treatment, and functional impact, are considered. A policy for medical certification following a diagnosis of myasthenia gravis is proposed.Jagathesan T, O'Brien MD. Myasthenia gravis and its aeromedical implications. Aerosp Med Hum Perform. 2017; 88(1):30-33.
[Mh] Termos MeSH primário: Aviação
Certificação
Miastenia Gravis/fisiopatologia
Pilotos
[Mh] Termos MeSH secundário: Adulto
Medicina Aeroespacial
Idoso
Azatioprina/uso terapêutico
Inibidores da Colinesterase/uso terapêutico
Bases de Dados Factuais
Glucocorticoides/uso terapêutico
Seres Humanos
Imunossupressores/uso terapêutico
Masculino
Meia-Idade
Miastenia Gravis/terapia
Prednisolona/uso terapêutico
Brometo de Piridostigmina/uso terapêutico
Estudos Retrospectivos
Timectomia
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Glucocorticoids); 0 (Immunosuppressive Agents); 9PHQ9Y1OLM (Prednisolone); KVI301NA53 (Pyridostigmine Bromide); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170221
[Lr] Data última revisão:
170221
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE
[do] DOI:10.3357/AMHP.4724.2017


  9 / 1490 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27823896
[Au] Autor:Feriani DJ; Souza GIH; Carrozzi NM; Mostarda C; Dourado PMM; Consolim-Colombo FM; De Angelis K; Moreno H; Irigoyen MC; Rodrigues B
[Ad] Endereço:Human Movement Laboratory, São Judas Tadeu University - USJT, São Paulo, SP, Brazil; Faculty of Physical Education, University of Campinas - UNICAMP, Campinas, SP, Brazil.
[Ti] Título:Impact of exercise training associated to pyridostigmine treatment on autonomic function and inflammatory profile after myocardial infarction in rats.
[So] Source:Int J Cardiol;227:757-765, 2017 Jan 15.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The effects of exercise training (ET) associated with pyridostigmine bromide (PYR) treatment on cardiac and autonomic function, as well as on inflammatory profile after myocardial infarction (MI), are unclear. METHODS: Male Wistar rats were randomly assigned to: control (C); sedentary+infarcted (I); sedentary+infarcted treated with PYR (IP); infarcted submitted to aerobic exercise training (IT); and infarcted submitted to treatment with PYR and aerobic exercise training (ITP). After 12weeks of ET (50-70% maximal running speed; 1h a day, 5days a week) and/or PYR treatment (0.14mg/mL on drink water), hemodynamic, autonomic and cytokines expression were performed. RESULTS: We observed that both aerobic ET, associated or not with PYR treatment in MI animals, were able to: reduced MI area, improved systolic and diastolic function, baroreflex sensitivity, cardiovascular autonomic modulation, and tonic activity of the sympathetic and parasympathetic nervous system. Also, they led to a reduction of inflammatory profile measured at plasma, left ventricle and soleus skeletal muscle. However, additional effects were observed when ET and PYR were associated, such as an increase in vagal tonus and modulation, reduction of MI area, interferon-γ and tumor necrosis factor-α (TNF-α), as well as an increase of interleukin-10/TNF-α ratio on left ventricle. CONCLUSION: These data suggest that associating ET and PYR promotes some additional benefits on cardiovascular autonomic modulation and inflammatory profile in infarcted rats.
[Mh] Termos MeSH primário: Mediadores da Inflamação/sangue
Infarto do Miocárdio/sangue
Infarto do Miocárdio/terapia
Condicionamento Físico Animal
Brometo de Piridostigmina/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Barorreflexo/fisiologia
Inibidores da Colinesterase/farmacologia
Inibidores da Colinesterase/uso terapêutico
Mediadores da Inflamação/antagonistas & inibidores
Masculino
Condicionamento Físico Animal/métodos
Brometo de Piridostigmina/farmacologia
Distribuição Aleatória
Ratos
Ratos Wistar
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Inflammation Mediators); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161109
[St] Status:MEDLINE


  10 / 1490 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27796041
[Au] Autor:Huh H; Park SJ; Lim HH; Jung KY; Baek SK; Yoon SZ; Lee HW; Lim HJ; Cho JE
[Ad] Endereço:Department of Anesthesiology and Pain Medicine, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
[Ti] Título:Optimal anesthetic regimen for ambulatory laser microlaryngeal surgery.
[So] Source:Laryngoscope;127(5):1135-1139, 2017 May.
[Is] ISSN:1531-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES/HYPOTHESIS: Laser microlaryngeal surgery (LMS) is a short operation requiring brief and intense paralysis. Adequate muscle relaxation and rapid recovery of neuromuscular function are essential for improving surgical conditions and reducing the incidence of complications during LMS. However, the ideal muscle relaxant with a rapid onset and short duration of action is not yet available. Rocuronium has rapid onset at higher doses, but with a prolonged duration of action. Sugammadex is a selective relaxant-binding agent that allows for rapid reversal of rocuronium-induced neuromuscular blockade. This study aimed to compare the surgical conditions and anesthesia time between two combinations of neuromuscular blocker and reversal agent, rocuronium-sugammadex (R-S) and succinylcholine-cisatracurium-pyridostigmine (S-C-P), and propose an optimal anesthetic regimen for improving the surgical conditions in LMS patients. STUDY DESIGN: Prospective, randomized, double-blinded clinical study. METHODS: Patients in the R-S group received 1 mg/kg rocuronium bromide, whereas those in the S-C-P group received 1 mg/kg succinylcholine. After endotracheal intubation, 0.08 mg/kg cisatracurium was injected in S-C-P patients. After the procedure, R-S patients received 2 mg/kg sugammedex, whereas S-C-P patients received 0.2 mg/kg pyridostigmine plus 10 µg/kg atropine. RESULTS: In the R-S group, surgical condition scores were significantly higher and anesthesia time was significantly shorter. The use of additive neuromuscular blocking agents was significantly higher in the S-C-P group. CONCLUSIONS: Muscle relaxation with rocuronium and reversal with sugammadex resulted in better surgical conditions and a shorter anesthesia time in patients undergoing LMS when compared to the S-C-P regimen. LEVEL OF EVIDENCE: 1b Laryngoscope, 127:1135-1139, 2017.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos Ambulatórios
Androstanóis/administração & dosagem
Atracúrio/análogos & derivados
Inibidores da Colinesterase/administração & dosagem
Doenças da Laringe/cirurgia
Terapia a Laser/métodos
Bloqueio Neuromuscular/métodos
Bloqueadores Neuromusculares/administração & dosagem
Fármacos Neuromusculares Despolarizantes/administração & dosagem
Fármacos Neuromusculares não Despolarizantes/administração & dosagem
Brometo de Piridostigmina/administração & dosagem
Succinilcolina/administração & dosagem
gama-Ciclodextrinas/administração & dosagem
[Mh] Termos MeSH secundário: Atracúrio/administração & dosagem
Método Duplo-Cego
Feminino
Seres Humanos
Intubação Intratraqueal
Masculino
Meia-Idade
Estudos Prospectivos
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androstanols); 0 (Cholinesterase Inhibitors); 0 (Neuromuscular Blocking Agents); 0 (Neuromuscular Depolarizing Agents); 0 (Neuromuscular Nondepolarizing Agents); 0 (gamma-Cyclodextrins); 2GQ1IRY63P (Atracurium); 361LPM2T56 (Sugammadex); J2R869A8YF (Succinylcholine); KVI301NA53 (Pyridostigmine Bromide); QX62KLI41N (cisatracurium); WRE554RFEZ (rocuronium)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE
[do] DOI:10.1002/lary.26368



página 1 de 149 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde